Amicus Therapeutics (FOLD) Income Statement

Click line-items for a historical chart and %

Revenue:
Research revenue
Collaboration revenue
Total revenue
Operating Expenses:
Research and development	32.46M
General and administrative
Restructuring charges	11K
Impairment of leasehold improvements
Depreciation and amortization
In-process research and development
Total operating expenses	46.72M
Loss from operations	-44.94M
Other income (expenses):
Interest income	460K
Interest expense	-1.52M
Change in fair value of warrant liability
Other income
Loss before tax benefit
Benefit from income taxes	253K
Net loss	-46.65M
Deemed dividend
Preferred stock accretion
Net loss attributable to common stockholders
Net loss attributable to common stockholders per common shares - basic and diluted	-0.33
Weighted-average common shares outstanding - basic and diluted

Entities mentioned with FOLD